Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Fecal metabolomics: assay performance and association with colorectal cancer.

Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R.

Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131.

2.

Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations.

Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ.

PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126.

3.

Non-invasive fecal metabonomic detection of colorectal cancer.

Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC.

Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625.

4.

Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults.

Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP.

PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803.

5.

Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces.

Phua LC, Koh PK, Cheah PY, Ho HK, Chan EC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Oct 15;937:103-13. doi: 10.1016/j.jchromb.2013.08.025.

PMID:
24029555
6.

Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection.

Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB.

BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.

7.

Evaluation of specific fecal protein biochips for the diagnosis of colorectal cancer.

Wang HP, Wang YY, Pan J, Cen R, Cai YK.

World J Gastroenterol. 2014 Feb 7;20(5):1332-9. doi: 10.3748/wjg.v20.i5.1332.

8.

Metabolites of tobacco smoking and colorectal cancer risk.

Cross AJ, Boca S, Freedman ND, Caporaso NE, Huang WY, Sinha R, Sampson JN, Moore SC.

Carcinogenesis. 2014 Jul;35(7):1516-22. doi: 10.1093/carcin/bgu071.

9.

Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.

Caviglia GP, Cabianca L, Fagoonee S, Gili FM.

Biochem Med (Zagreb). 2016;26(1):114-20. doi: 10.11613/BM.2016.012.

10.

Altered tissue metabolites correlate with microbial dysbiosis in colorectal adenomas.

Nugent JL, McCoy AN, Addamo CJ, Jia W, Sandler RS, Keku TO.

J Proteome Res. 2014 Apr 4;13(4):1921-9. doi: 10.1021/pr4009783.

11.

Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer.

Guertin KA, Loftfield E, Boca SM, Sampson JN, Moore SC, Xiao Q, Huang WY, Xiong X, Freedman ND, Cross AJ, Sinha R.

Am J Clin Nutr. 2015 May;101(5):1000-11. doi: 10.3945/ajcn.114.096099.

12.

Development of high-performance chemical isotope labeling LC-MS for profiling the human fecal metabolome.

Xu W, Chen D, Wang N, Zhang T, Zhou R, Huan T, Lu Y, Su X, Xie Q, Li L, Li L.

Anal Chem. 2015 Jan 20;87(2):829-36. doi: 10.1021/ac503619q.

13.

Metabolomics in nutritional epidemiology: identifying metabolites associated with diet and quantifying their potential to uncover diet-disease relations in populations.

Guertin KA, Moore SC, Sampson JN, Huang WY, Xiao Q, Stolzenberg-Solomon RZ, Sinha R, Cross AJ.

Am J Clin Nutr. 2014 Jul;100(1):208-17. doi: 10.3945/ajcn.113.078758.

14.

A prospective study of serum metabolites and colorectal cancer risk.

Cross AJ, Moore SC, Boca S, Huang WY, Xiong X, Stolzenberg-Solomon R, Sinha R, Sampson JN.

Cancer. 2014 Oct 1;120(19):3049-57. doi: 10.1002/cncr.28799.

15.

Metabolomics in epidemiology: sources of variability in metabolite measurements and implications.

Sampson JN, Boca SM, Shu XO, Stolzenberg-Solomon RZ, Matthews CE, Hsing AW, Tan YT, Ji BT, Chow WH, Cai Q, Liu DK, Yang G, Xiang YB, Zheng W, Sinha R, Cross AJ, Moore SC.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):631-40. doi: 10.1158/1055-9965.EPI-12-1109.

16.

Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.

Shastri YM, Naumann M, Oremek GM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein JM.

Int J Cancer. 2006 Dec 1;119(11):2651-6.

17.

Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification.

Wolahan SM, Hirt D, Glenn TC.

In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 25.

18.

Fecal microRNA profile in patients with colorectal carcinoma before and after curative surgery.

Rotelli MT, Di Lena M, Cavallini A, Lippolis C, Bonfrate L, Chetta N, Portincasa P, Altomare DF.

Int J Colorectal Dis. 2015 Jul;30(7):891-8. doi: 10.1007/s00384-015-2248-0.

PMID:
25989926
19.

Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients.

Yang RN, Yang SH, Chang CC, Chien CC, Pan S, Huang CJ.

Genet Test Mol Biomarkers. 2010 Oct;14(5):703-8. doi: 10.1089/gtmb.2010.0047.

PMID:
20854102
20.

Metabolite analysis of human fecal water by gas chromatography/mass spectrometry with ethyl chloroformate derivatization.

Gao X, Pujos-Guillot E, Martin JF, Galan P, Juste C, Jia W, Sebedio JL.

Anal Biochem. 2009 Oct 15;393(2):163-75. doi: 10.1016/j.ab.2009.06.036.

PMID:
19573517

Supplemental Content

Support Center